PMID- 8077666
OWN - NLM
STAT- MEDLINE
DCOM- 19941005
LR  - 20061115
IS  - 0022-1767 (Print)
IS  - 0022-1767 (Linking)
VI  - 153
IP  - 6
DP  - 1994 Sep 15
TI  - Effective graft-versus-leukemia effects independent of graft-versus-host disease 
      after T cell-depleted allogeneic bone marrow transplantation in a murine model of 
      B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
PG  - 2562-7
AB  - After allogeneic bone marrow transplantation (BMT) for leukemia, beneficial 
      graft-vs-leukemia (GVL) effects are usually accompanied by potentially serious 
      graft-vs-host disease (GVHD). Because T cell depletion is the only effective way 
      to prevent GVHD it seems important to understand whether effective GVL can 
      develop after BMT with T cell depletion in GVHD-free recipients. Well-established 
      C57BL/6-->BALB/c chimeras that were free of GVHD, reconstituted with T 
      cell-depleted allogeneic bone marrow cells, and inoculated 3 mo after BMT with a 
      high inoculation of murine B cell leukemia (BCL1) showed no evidence of disease, 
      whereas all control mice developed leukemia and died within 58 days. Results from 
      adoptive transfer experiments in secondary naive BALB/c recipients indicated that 
      all BCL1 cells were eliminated in the chimeras within 14 days. Hence, complete 
      resistance to BCL1 developed in the chimeras despite complete tolerance to host 
      alloantigens. The GVL effects observed in tolerant chimeras were further 
      amplified by administration of immunocompetent allogeneic C57BL/6 spleen cells, 
      low dose rIL-2, or both for 5 days. Our data suggest that GVL effects can develop 
      even after T cell depletion in the absence of clinically overt GVHD and that GVL 
      can be further amplified by rIL-2, either with or without use of additional 
      immunocompetent donor T cells. Our data may provide the basis for new approaches 
      to induce effective GVL after allogeneic BMT with cell therapy and rIL-2 at the 
      stage of minimal residual disease, while avoiding early GVHD induced by the BMT 
      procedure.
FAU - Weiss, L
AU  - Weiss L
AD  - Department of Bone Marrow Transplantation, Hadassah University Hospital, 
      Jerusalem, Israel.
FAU - Lubin, I
AU  - Lubin I
FAU - Factorowich, I
AU  - Factorowich I
FAU - Lapidot, Z
AU  - Lapidot Z
FAU - Reich, S
AU  - Reich S
FAU - Reisner, Y
AU  - Reisner Y
FAU - Slavin, S
AU  - Slavin S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (Interleukin-2)
SB  - IM
MH  - Animals
MH  - Bone Marrow Cells
MH  - Bone Marrow Transplantation/*immunology
MH  - Female
MH  - Graft vs Host Disease/*immunology
MH  - Immune Tolerance/immunology
MH  - Immunotherapy, Adoptive
MH  - Interleukin-2/therapeutic use
MH  - Leukemia, B-Cell/immunology/*therapy
MH  - Lymphoma, B-Cell/immunology/therapy
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - T-Lymphocytes/immunology
MH  - Transplantation Chimera/immunology
MH  - Transplantation, Homologous
EDAT- 1994/09/15 00:00
MHDA- 1994/09/15 00:01
CRDT- 1994/09/15 00:00
PHST- 1994/09/15 00:00 [pubmed]
PHST- 1994/09/15 00:01 [medline]
PHST- 1994/09/15 00:00 [entrez]
PST - ppublish
SO  - J Immunol. 1994 Sep 15;153(6):2562-7.